HC Wainwright Lifts Earnings Estimates for ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) – Investment analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for ADC Therapeutics in a report released on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $19.00 million for the quarter, compared to analysts’ expectations of $19.01 million.

Several other research analysts also recently commented on the stock. Guggenheim decreased their price target on shares of ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. Stephens lifted their target price on shares of ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, ADC Therapeutics currently has a consensus rating of “Buy” and an average price target of $7.75.

ADC Therapeutics Stock Up 0.4 %

Shares of ADCT stock opened at $1.36 on Thursday. The firm has a market cap of $131.01 million, a P/E ratio of -0.57 and a beta of 1.51. The business has a 50-day moving average price of $1.64 and a two-hundred day moving average price of $2.22. ADC Therapeutics has a 12-month low of $1.28 and a 12-month high of $5.38.

Institutional Investors Weigh In On ADC Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC purchased a new position in shares of ADC Therapeutics in the 3rd quarter valued at approximately $41,000. Charles Schwab Investment Management Inc. boosted its position in ADC Therapeutics by 10.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 194,258 shares of the company’s stock worth $612,000 after purchasing an additional 18,796 shares during the last quarter. FMR LLC purchased a new position in shares of ADC Therapeutics during the 3rd quarter worth $167,000. MetLife Investment Management LLC lifted its position in ADC Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 43,089 shares of the company’s stock valued at $136,000 after purchasing an additional 24,279 shares in the last quarter. Finally, Redmile Group LLC grew its stake in shares of ADC Therapeutics by 2.6% during the 3rd quarter. Redmile Group LLC now owns 15,669,217 shares of the company’s stock valued at $49,358,000 after acquiring an additional 400,000 shares during the period. Hedge funds and other institutional investors own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.